Expert Video - How is lower-risk MDS treated?

MDS experts, Dr Alan List and Dr David Sallman, explain that the goals of therapy for patients with lower-risk myelodysplastic syndromes (MDS) are to improve blood counts and alleviate symptoms. The treatment options for lower-risk MDS discussed are: recombinant erythropoietin, lenalidomide, immunosuppressive therapy, and hypomethylating agents. They also discuss watchful waiting if a patient with lower-risk MDS has no symptoms or doesn’t have very low blood cell counts.

  • Share with family and friends:

Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about MDS which will help other patients, caregivers and families.

Please rate this content:

This educational activity has been developed by the Myelodysplastic Syndromes Foundation, Inc. and Mechanisms in Medicine Inc.

This activity is supported by an educational grant from Acceleron Pharma, Celgene Corporation, Jazz Pharmaceuticals, Novartis, and Takeda Oncology.

This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.